On May, 8 Corbus Pharmaceuticals Holdings, Inc. (CRBP) Analysts See $-0.14 EPS

April 16, 2018 - By Darrel Chase

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Corporate Logo

On May, 8 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)’s earnings report is anticipated by WallStreet, according to Zacks. Analysts forecast 12.50 % diference or $-0.14 from the $-0.16 EPS from 2017. Wall Street now forecasts -30.00 % EPS growth despite Corbus Pharmaceuticals Holdings, Inc. last quarter’s EPS of $-0.20. CRBP reached $6.6 on during the last trading session after $0.3 change.Corbus Pharmaceuticals Holdings, Inc. has volume of 473,309 shares. Since April 17, 2017 CRBP has declined 38.80% and is downtrending. The stock underperformed the S&P 500 by 50.35%.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Ratings Coverage

In total 3 analysts cover Corbus Pharmaceuticals (NASDAQ:CRBP). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 10 are the (NASDAQ:CRBP)’s analyst reports since October 19, 2017 according to StockzIntelligence Inc. On Friday, November 10 the firm has “Buy” rating given by Noble Financial. On Thursday, December 14 the stock has “Buy” rating by Cantor Fitzgerald. On Monday, March 12 the rating was maintained by Cantor Fitzgerald with “Buy”. On Thursday, January 18 Raymond James initiated the shares of CRBP in report with “Buy” rating. On Monday, January 29 the rating was maintained by Cantor Fitzgerald with “Buy”. The company rating was maintained by Noble Financial on Monday, February 5. On Friday, December 15 the rating was maintained by Noble Financial with “Buy”. On Thursday, October 19 the stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has “Buy” rating given by Cantor Fitzgerald. On Saturday, December 23 Noble Financial maintained Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) with “Buy” rating. On Monday, November 6 the rating was maintained by Cantor Fitzgerald with “Buy”.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases.The firm is worth $377.09 million. The Company’s lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases.Currently it has negative earnings.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.